Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening
Year: 2020
Type: review
Abstract: Neurodegenerative diseases represent a significant unmet medical need in our aging society. There are no effective treatments for most of these diseases, and we know comparatively little regarding pathogenic mechanisms. Among the challenges faced by those involved in developing therapeutic drugs for neurodegenerative diseases, the syndromes are often complex, and small animal models do not fully recapitulate the unique features of the human nervous system. Human induced pluripotent stem cells (iPSCs) are a novel technology that ideally would permit us to generate neuronal cells from individual patients, thereby eliminating the problem of species-specificity inherent when using animal models. Specific phenotypes of iPSC-derived cells may permit researchers to identify sub-types and to distinguish among unique clusters and groups. Recently, iPSCs were used for drug screening and testing for neurologic disorders including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), spinocerebellar atrophy (SCA), and Zika virus infection. However, there remain many challenges still ahead, including how one might effectively recapitulate sporadic disease phenotypes and the selection of ideal phenotypes and for large-scale drug screening. Fortunately, quite a few novel strategies have been developed that might be combined with an iPSC-based model to solve these challenges, including organoid technology, single-cell RNA sequencing, genome editing, and deep learning artificial intelligence. Here, we will review current applications and potential future directions for iPSC-based neurodegenerative disease models for critical drug screening.
Source: Molecules
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: induced pluripotent stem cells, neurodegenerative diseases, disease modeling, drug screening, iPSC-derived neurons, Alzheimer's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, Zika virus infection, organoids, single-cell RNA sequencing, genome editing, deep learning, disease heterogeneity
Open Access status: gold
Estimated APC paid: $2,112
Awards: Inhibition of Tumor Stroma-Stimulated Proliferation and Enhanced Chemotherapeutic Effects by Reducing Hedgehog Signaling in Pancreatic Ductal Adenocarcinoma with Novel Dna Methyltransferase Inhibitors., Aiming Candidate Dopaminergic Neuron Sub-Populations Derived from Ipscs for High Efficiency, Survival Rate and Migration Ability Cell Transplantation Therapy of Parkinson Disease(I), G497937365, G5350428698, The Novel Application of Candidates Targeting Pgc1-Alpha and Rarres2 in Metabolic Disorders: Increase of Mitochondrial Energy Expenditure via Ucp1 Induction Promotes White-To-Brown Fat Conversion, G6282059440, G737106015, Igf-1, Canonical Wnt and Other Signaling Pathways Are Potentially Involved in Therapeutic Mechanisms of the Small Compound Screened from Amyotrophic Lateral Sclerosis Induced Pluripotent Stem Cells Derived Motor Neurons( I ), G939887807
OpenAlex ID: W3019943712
